Evidence map›Paper›PMID 40362760›Full record

ReviewNutrients2025

Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients.

Andrea Sechi, Stephano Cedirian, Tullio Brunetti, Federico Quadrelli, Fernanda Torres, Antonella Tosti, Fabio Rinaldi, Daniela Pinto, Rolando Bolognino, Angelo Valerio Marzano and 1 more

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea SechiDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20120 Milan, Italy.ORCID 0000-0003-3026-2434
Stephano CedirianDermatology Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy.ORCID 0000-0002-9783-7864
Tullio BrunettiDermatology Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy.ORCID 0009-0006-6318-2739
Federico QuadrelliDermatology Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy.ORCID 0000-0002-2650-4616
Fernanda TorresPrivate Practice, Rio de Janeiro 22410-000, Brazil.
Antonella TostiFredric Brandt Endowed Professor of Dermatology, Miller School of Medicine, University of Miami, Miami, FL 33146, USA.
Fabio RinaldiHuman Microbiome Advanced Project (HMAP), 20129 Milan, Italy.
Daniela PintoHuman Microbiome Advanced Project (HMAP), 20129 Milan, Italy.ORCID 0000-0001-8107-106X
Rolando BologninoSapienza University of Rome, Unitelma Sapienza, 00185 Rome, Italy.
Angelo Valerio MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20120 Milan, Italy.ORCID 0000-0002-8160-4169
Bianca Maria PiracciniDermatology Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy.ORCID 0000-0001-6537-9689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the distressing side effects of cancer treatments, hair loss is one of the most disturbing for the quality of life and adherence to therapy in breast cancer patients. Many patients take nutritional supplements to prevent hair loss or enhance regrowth. Based on their mechanism and timing of use, nutritional supplements could be divided into safe, cautious, debated, and contraindicated categories. Non-contraindicated supplements generally include safe supplements like vitamin D, which is not known to interfere with cancer treatments. Those that are contraindicated include phytoestrogens and compounds affecting estrogen pathways because of the risk of stimulating tumor growth in cancers sensitive to estrogen. Antioxidants like tocotrienols and resveratrol are given judiciously because of potential interference with cancer therapies dependent on reactive oxygen species. Supplements debated, including nicotinamide, folate, and iron, pose a risk by promoting cellular proliferation or altering the tumor microenvironment. Biotin is nontoxic but interferes with blood test results and is thus difficult in cancer monitoring. Evidence regarding nutritional supplements' safety and efficacy in this context is conflicting. Management by an oncologist is required along with more studies to clearly establish the safety parameters and efficacy guidelines.

Indexed as

AlopeciaBreast NeoplasmsDietary SupplementsAntioxidantsFemaleHumansQuality of LifeVitamin DAntioxidantsVitamin Dbreast cancerchemotherapy-induced alopeciahair lossimmunotherapysafety profiletargeted therapytelogen effluvium

Identifiers

PMID40362760
PMCPMC12073702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.